---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-002986"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T22:51:16.132249+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MaxCyte Q4 revenue $15.7M (+26% YoY) but core down 32%; net loss $5.3M; reiterates 2024 guidance

## Summary
- Q4 total revenue $15.7M (+26% YoY); core business revenue $7.2M (-32%); SPL program-related $8.5M (+359%).
- Full year 2023 revenue $41.3M (-7% YoY); net loss $37.9M vs. $23.6M loss in 2022.
- Cash, equivalents and investments $211.2M at Dec 31, 2023; expects ~$175M at end of 2024.
- 23 active SPLs at year-end, 3 more signed in Jan 2024 (now 26); 16 licensed clinical programs.
- 2024 guidance: core revenue flat to +5% YoY; SPL program-related ~$3M; excludes CASGEVY milestones.

## SEC filing metadata
- accession: 0001558370-24-002986
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837024002986/0001558370-24-002986-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837024002986/mxct-20240312x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-002986
- JSON: https://secwatch.observer/filing/0001558370-24-002986.json
- Plain text: https://secwatch.observer/filing/0001558370-24-002986.txt

## Key facts
- Earnings Releases
  MAXCYTE, INC. reported quarter and year ended December 31, 2023 results: revenue Total revenue of $15.7 million in the fourth quarter of 2023, net income Fourth quarter 2023 net loss was $5.3 million. Guidance reaffirmed.
  - Period: quarter and year ended December 31, 2023
  - Revenue: Total revenue of $15.7 million in the fourth quarter of 2023
  - Net income: Fourth quarter 2023 net loss was $5.3 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
  evidence_url: https://www.sec.gov/Archives/edgar/data/1287098/000155837024002986/0001558370-24-002986-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.